Additionally, SGLT2 inhibitors, the novel class of antidiabetics with pleiotropic effects, have unequivocally demonstrated protective properties in alleviating mitochondrial dysfunction, oxidative stress, and inflammation, regardless the presence or the absence of diabetes [108–111]. The gene discussed is SLC5A2; the disease is diabetes mellitus.